

Eficacia y seguridad de la Ketamina en una paciente con depresión, síntomas psicóticos, enfermedad cardiovascular y riesgo de inanición

Safety and efficacy of Ketamine in a patient with psychotic depression, cardiovascular disease, and starvation risk

Efraín Alberto Trejos Orozco ^a, Julio César Gutiérrez Segura ^b, Sergio Andrés Ochoa Orozco ^c.

- a. Medical student. Universidad Tecnológica of Pereira. ORCID: <https://orcid.org/0000-0003-0544-4658>.
- b. MD. Specialist in liaison psychiatry. Head professor. Universidad Tecnológica of Pereira. ORCID: <https://orcid.org/0000-0001-9746-612X>.
- c. MD. Specialist in psychiatry. Mental University Hospital of Risaralda. Professor. Medicine program. Fundación Universitaria Autónoma de las Américas. ORCID: <https://orcid.org/0000-0002-1915-7222>.

DOI: [10.22517/25395203.24966](https://doi.org/10.22517/25395203.24966)

Abstract

Introduction: There has been a rising interest in ketamine as a promising treatment for refractory depression. Despite this, there is uncertain knowledge regarding aspects of the routinary use of ketamine for treating depression, such as optimal doses, long term toxicity, abuse potential in depressed patients, probable adverse effects associated with antidepressant drugs, the indication of ketamine in psychotic patients, and the ethical concerns of ketamine use.

Clinical case: A 63-year-old woman with a psychotic depressive episode, catatonic features, cardiovascular disease (patent foramen ovale and atrial fibrillation), and starvation risk because she refused food intake. She was sent to electroconvulsive therapy (ECT) after several weeks of oral administration of benzodiazepine, antipsychotic, and antidepressant medications; the patient presented no improvement, but she was rejected due to her cardiovascular comorbidity. Two IV Ketamine doses were used as a life-saving strategy with good clinical response, mainly in terms of the catatonic features. The ketamine treatment was not only effective but also well tolerated.

Discussion: Despite the little information regarding its use in psychotic and catatonic patients, this case would suggest that it remains effective and safe, as well as a good option for patients with cardiovascular disease and those who cannot use electroconvulsive therapy.

Key Words: Ketamine, depression.

Introduction

There has been a rising interest in Ketamine as a promising treatment for refractory depression over the last decade (1). Besides, it seems to be well-tolerated despite some acute and mild side effects (2). However, there is uncertain knowledge regarding several aspects of the routine use of ketamine for depression, such as optimal doses, long term toxicity, abuse potential in depressed patients, probable adverse effects associated with antidepressant drugs, the indication of ketamine in psychotic patients, and the ethical concerns of Ketamine use (1, 3).

In this report, we present a clinical case of a 63-year-old woman with a depressive episode, along with psychotic and catatonic features, who suffers from a cardiovascular disease and starvation risk. She was treated with ketamine with positive clinical response and tolerability.

Case presentation

A 63-year-old woman was referred to the general hospital from a psychiatric institution where she was receiving treatment for her second psychotic depressive episode (the previous episode was treated 3 years before with Quetiapine and Sertraline). She had nihilistic delusions, she refused to bathe and to receive food or medications for 1 month, which caused a clinical deterioration in the last week. She had a medical record of a patent foramen ovale and atrial fibrillation treated with anticoagulation. At the hospital, she continued with depression, psychotic, and catatonic features, and she refused food and medication intake. Enteral nutrition was conducted by nasogastric tube; in addition, sertraline, olanzapine, and lorazepam were administered for two weeks without significant improvement.

After two more weeks of treatment with a nasogastric tube, the patient remained with hyporexia and catatonic features, also the antidepressant and antipsychotic doses were increased. She was sent to electroconvulsive therapy, but she was not admitted due to her medical cardiovascular record and anticoagulation medicine intake.

« *In this report, we present a clinical case of a 63 years old woman with a depressive episode, and psychotic and catatonic features, who suffers from a cardiovascular disease and starvation risk.* »

At the general hospital, Ketamine was considered as the last option for the patient. The internist and the anesthesiologist approved its use on day 1 and 5 in a 0.5mg/kg dose for slow IV ketamine infusion (40 minutes), as it has been used in clinical studies (4).

Since the second day of administration, she began to eat fruits, and a reduction in catatonic features was observed. After 1 week, the patient was eating small pieces of food, remained psychotic and depressed, but she was performing basic activities without catatonic features. She was taken back to the psychiatric hospital to continue the treatment with quetiapine and sertraline.

The patients' husband gave approval for ketamine use and for publishing the clinical case in academic reports.

Discussion

Ketamine is an old and well-known drug studied for anesthetic indications since 1964. With the first clinical reports, its abuse potential was detected, especially in patients with depression. It was only until the 1990's that Ketamine emerged as a proposed treatment for depression (5).

Clinical studies have shown a Ketamine response rate around 50% in patients with treatment-resistant depression. The Ketamine doses in clinical studies range from 0.2mg/kg and 0.6mg/kg, with better outcomes at 0.5mg/kg (4). Despite the clinical reports indicating short effectiveness for Ketamine improvement, its repeated administration can maintain and prolong the response (4). In this clinical case, a 0.5mg/kg repeated administration was used based on clinical results.

The mechanisms underlying the ketamine antidepressant activity are unknown, but recent studies suggest that increased levels of regional alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation and brain-derived neurotrophic factor (BDNF) expression, as well as enhanced synaptic plasticity are involved in the process (6).

Some authors declare their concern about using ketamine for depression in the clinical context without following research protocols, due to the lack of proven efficacy, poor recovery time, and abuse potential (1). In our case, we considered the risk of starvation and infections associated with the nasogastric tube as an indication to use ketamine as a life-saving strategy since other studies have focused on the ketamine potential to treat suicidal ideation in high-risk patients (7).

The Colombian depressive disorder clinical guidelines recommend treatment with antidepressant and antipsychotic drugs in cases of psychotic depression; however, ketamine is not recommended (8). The use of ketamine was a risk against benefit choice in this case considering the internal medicine, anesthesiologist, and family considerations.

Conclusions

Despite the little information regarding its use in psychotic and catatonic patients, this case would suggest that ketamine remains effective and well tolerated, as well as an advantageous option for patients with cardiovascular disease and those who cannot be treated with electroconvulsive therapy.

References

1. Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. *Lancet Psychiatry*. 2017 May;4(5):419-426. doi: 10.1016/S2215-0366(17)30102-5
2. Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. *Lancet Psychiatry*. 2018 Jan;5(1):65-78. doi: 10.1016/S2215-0366(17)30272-9.
3. Loo C. Can we confidently use ketamine as a clinical treatment for depression? *Lancet Psychiatry*. 2018 Jan;5(1):11-12. doi: 10.1016/S2215-0366(17)30480-7.
4. Blier P., Blier J. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders. In: Mathew S., Zarate, Jr. C. (eds) *Ketamine for Treatment-Resistant Depression*. 2016. Adis, Cham. https://doi.org/10.1007/978-3-319-42925-0_3
5. Chang L.C., Rajagopalan S., Mathew S.J. (2016) The History of Ketamine Use and Its Clinical Indications. In: Mathew S., Zarate, Jr. C. (eds) *Ketamine for Treatment-Resistant Depression*. Adis, Cham. https://doi.org/10.1007/978-3-319-42925-0_1
6. Hermes G., Sanacora G. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies. In: Mathew S., Zarate, Jr. C. (eds) *Ketamine for Treatment-Resistant Depression*. 2016. Adis, Cham. doi.org/10.1007/978-3-319-42925-0_6
7. Ballard E.D., Price R.B. (2016) Ketamine and Suicide Risk. In: Mathew S., Zarate, Jr. C. (eds) *Ketamine for Treatment-Resistant Depression*. 2016. Adis, Cham. doi.org/10.1007/978-3-319-42925-0_4
8. Bohórquez Peñaranda AP, García Valencia J, Rodríguez Guarín M, Arenas Borrero ÁE, Castro Díaz SM, de la Hoz Bradford AM, et al. Guía de atención integral para la detección temprana y diagnóstico del episodio depresivo y trastorno depresivo recurrente en adultos. Atención integral de los adultos con diagnóstico de episodio depresivo o trastorno depresivo recurrente. Parte III: Tratamiento de la depresión resistente y la depresión con psicosis, tratamiento con terapia ocupacional y hospital día. *Revista Colombiana de Psiquiatría*. 2012;41(4):774-86.